Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27 2024 - 9:15AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced a research collaboration
with the National Cancer Center Hospital East (NCCHE) in Japan to
study the prognostic and predictive value of molecular residual
disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will use
Myriad’s ultra-sensitive MRD test, Precise MRD, to monitor
circulating tumor DNA (ctDNA) over time in patients diagnosed with
a wide array of solid tumor and hematological cancers.
The SCRUM-MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino of
the NCCHE, will explore how multi-omic profiling can be used to
develop more personalized treatment and therapeutic strategies in
three study cohorts. Two of the three cohorts, including
approximately 1,200 patients across more than 20 cancer types, will
undergo MRD monitoring via Precise MRD. The goal of
SCRUM-MONSTAR-SCREEN-3 is to generate high-quality, prospective,
clinical evidence showing MRD testing can be broadly applied across
cancer types and to patients with different disease severity or
staging.
“First generation MRD tests have made remarkable progress
monitoring disease recurrence and progression in cancer types with
high tumor or variant burden. However, the SCRUM-MONSTAR-SCREEN-3
study requires an MRD test that is sensitive enough to use for
cancers with low tumor shedding or variant burden,” said Dr.
Yoshino, Deputy Director of Hospital East, Head, Division for the
Promotion of Drug and Diagnostic Development, Chief, Department of
Gastrointestinal Oncology at NCCHE. “We are pleased to partner with
Myriad, as its MRD assay is uniquely capable of detecting ctDNA at
the lowest levels of detection, a necessary attribute for a
pan-cancer study. This study has the potential to revolutionize the
scope of WGS-based MRD projects and foster the development of
MRD-guided therapeutic strategies for a broad spectrum of
cancers.”
“We are thrilled to be collaborating with the esteemed NCCHE
team on the SCRUM-MONSTAR-SCREEN-3 study. Investigators at NCCHE
have been at the forefront of MRD research, leading some of the
most groundbreaking and influential trials as part of
SCRUM-MONSTAR-SCREEN, including CIRCULATE-Japan, which comprises
GALAXY, VEGA, and ALTAIR in colorectal cancer patients,” said Dale
Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “We’ve
designed Precise MRD to be highly sensitive for application across
all cancer types and look forward to this study demonstrating its
utility in cancer care.”
About Myriad’s Precise MRDMyriad’s Precise MRD
is a tumor-informed, whole genome sequencing (WGS) based test that
monitors hundreds to thousands of tumor-specific variants, which
enables exceptional sensitivity and quantification of circulating
tumor DNA (ctDNA) in the blood of patients with cancer. Precise MRD
can be used to monitor ctDNA levels throughout a cancer patient’s
clinical care, starting immediately after diagnosis and continuing
through treatment and surveillance. The Precise MRD test is
available for use in research studies pursued jointly by Myriad and
academic or pharmaceutical investigators.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including that
Precise MRD is expected to have accurate ctDNA detection across
indication and the SCRUM-MONSTAR-SCREEN-3 study will explore how
multi-omic profiling can be used to develop more personalized
treatment and therapeutic strategies in three cohorts. These
“forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on March 1, 2023, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024